Rivastigmine is a novel intermediate-acting reversible non-competitive carbamate dual acetyl- and butyryl-cholinesterase inhibitor which is currently used for the treatment of AD [32], however, its mode of action is incompletely understood. Here, BCHE is linked to Alzheimer disease.